查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404796

美國流感診斷市場規模、佔有率和趨勢分析報告：按測試類型、最終用途和細分市場預測，2023-2030 年

U.S. Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture, Others), By End-use (Hospitals, POCT, Laboratories), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國流感診斷市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國流感診斷市場規模預計將達到2.829億美元，複合年成長率為5.9%。

市場的主要促進因素包括疾病盛行率上升、老年人口增加以及流感高風險族群，如兒童、孕婦和患有各種慢性病的免疫抑制患者。

美國流感盛行率的上升預計將推動市場成長。根據CDC資料，2018年10月和2018年11月流感發生率相對較低，但2018年12月有所上升，並保持較高水平，直到2019年2月。甲型流感在美國東南部流行。 2018-2019流感檢體期間，共檢測了536,301份實驗室檢體，其中54,381份呈陽性，其中甲型流感52,028檢體，乙型流感檢體。這些事實表明，流感疫情正在上升，對診斷產品的需求增加。

此外，兒童、孕婦、慢性病免疫抑制患者和醫護人員感染流感病毒的風險較高。例如，2018-2019 年 CDC 報告了 28 例兒童死亡，顯示疾病發生率增加。根據美國疾病管制與預防中心 (CDC) 的數據，2018-2019 年，有 1,654 名 65 歲以上的人被診斷出患有流感。由於其免疫抑制狀態，該族群容易感染流感和其他可能導致併發症的感染疾病。因此，透過家庭護理檢測套組促進及時診斷預計將在預測期內進一步推動市場成長。

RDIT 由於其易於獲得和易於使用，有利於快速診斷，因此在 2022 年佔據了最大的市場佔有率。此外，主要參與企業正在參與各種無機和有機策略開發，以擴大其現有產品系列併擴大地理範圍。例如，2018 年，Quidel 公司獲得了 FDA 510(k) 許可，用於快速診斷 A 型和 B 型流感的 CLIA 豁免 QuickVue A+B 型流感檢測。此檢測有助於透過患者的鼻咽和鼻拭子快速檢測 B&A 型流感抗原。

由於流感疫情加劇，2022年醫院將佔據最大的市場佔有率。由於主要企業提供技術先進的產品，POCT 成為成長最快的細分市場之一。例如，2016年，Becton, Dickinson, and Company推出了新型無線BD Veritor Plus系統，這是一種用於檢測B&A病毒亞型的快速診斷設備。該產品用於醫院、診所和實驗室。 BD Veritor Plus 系統由 BD 雲端連線解決方案組成，可讓使用者安全地將資料傳輸到電子健康記錄。預計這些因素將對預測期內的市場潛力產生正面影響。

美國流感診斷市場報告亮點

  • RIDT的商業性可用性和快速的交付時間是其龐大市場佔有率的主要因素。
  • RT-PCR領域在2022年佔了21.8%的市佔率。與細胞培養相比，RT-PCR 可以快速提供結果，從 2 分鐘到不到 2 小時。
  • 美國流感診斷醫院市場在2022年佔據最大市場佔有率，但預計隨著POCT的出現而逐漸放緩。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國流感診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 美國流感診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國流感診斷市場：測試類型估計和趨勢分析

  • 美國流感診斷市場：重點
  • 美國流感診斷市場：2022 年和 2030 年測試類型趨勢和市場佔有率分析
  • RIDT
  • RT-PCR
  • 細胞培養
  • 其他

第5章美國流感診斷市場：最終用途估計與趨勢分析

  • 美國流感診斷市場：重點
  • 美國流感診斷市場：2022 年和 2030 年最終用途趨勢和市場佔有率分析
  • 醫院
  • POCT
  • 實驗室

第6章美國流感診斷市場：競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • 3M
    • Abbott
    • BD
    • Meridian Bioscience
    • Quidel Corporation
    • F. Hoffmann-La Roche Ltd
    • SA Scientific Ltd.
    • SEKISUI Diagnostics
    • Thermo Fisher Scientific Inc.
Product Code: GVR-3-68038-788-9

U.S. Influenza Diagnostics Market Growth & Trends:

The U.S. influenza diagnostics market size is expected to reach USD 282.9 million by the year 2030 growing at a CAGR of 5.9% according to a new report by Grand View Research, Inc. Key drivers of the market include rising disease prevalence, increase in geriatric population and high-risk population for influenza such as children, pregnant women and immunosuppressed patients suffering from various chronic diseases.

The rise in the prevalence of the flu in the U.S. is expected to boost market growth. Data from CDC indicates that flu incidence was relatively low in the months of October 2018 and November 2018, however, rise in the number of cases was witnessed in December 2018 and remained high until February 2019. Influenza A was dominant in the southeastern part of the U.S. During 2018-2019 flu season, 536,301 specimens were tested in laboratories out of which 54,381 tested positive, among which 52,028 were of influenza A and 2,353 of influenza B. These facts are indicative of the rising prevalence of the flu, necessitating increasing demand for diagnostic products.

Additionally, individuals with a high risk of contracting the influenza virus consist of children, pregnant women, immunosuppressed patients suffering from chronic diseases and healthcare workers. For instance, 28 pediatric deaths have been reported by the CDC in 2018-2019 indicative of the rising disease incidence. According to the CDC in 2018-2019, 1654 individuals aged 65 years of age and above were diagnosed with flu. Owing to their immunosuppressed state, this population group is more susceptible to flu and other infectious diseases causing complications. Thus, timely diagnosis facilitated by home care testing kits is further anticipated to fuel the market growth during the forecast period.

RDITs held the largest market share in 2022 as they are easily available and are user-friendly facilitating rapid diagnosis. In addition, key participants are engaged in various inorganic and organic strategic developments to expand their existing product portfolios and geographic expansion. For instance, in 2018, Quidel Corporation received 510(k) FDA clearance for their CLIA waived QuickVue Influenza A+B assay to be used for the rapid diagnosis of influenza A & B. This assay facilitates rapid detection of influenza B & A antigens by nasopharyngeal and nasal swab from patients.

Hospitals held the largest market share in 2022 due to the rise in prevalence of flu. POCT is one of the fastest-growing segments due to technologically advanced products offered by leading players. For instance, in 2016, Becton, Dickinson, and Company launched a new wireless BD Veritor Plus System which is a rapid diagnostic device for the detection of B & A virus subtypes. This product serves hospitals, clinics, and laboratories. BD Veritor Plus System consists of BD cloud connectivity solution that allows users to transfer data securely to an electronic medical record. These factors are thus anticipated to positively impact market potential during the forecast period.

U.S. Influenza Diagnostics Market Report Highlights:

  • Commercial availability of RIDTs and quick turnaround times are major factors that attribute to its large market share.
  • The RT-PCR segment held a significant share of 21.8% of the market in 2022. It delivers results faster in comparison to cell culture, ranging from 2 minutes to less than 2 hours.
  • The hospitals market for U.S. influenza diagnostics held the largest market share in 2022 but is expected to gradually slow down with the advent of POCT.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test type
    • 1.1.2. End use
    • 1.1.3. Country scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Influenza Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. U.S. Influenza Diagnostics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. U.S. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. U.S. Influenza Diagnostics Market: Key Takeaways
  • 4.2. U.S. Influenza Diagnostics Market: Test Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. RIDT
    • 4.3.1. RIDT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. RT-PCR
    • 4.4.1. RT-PCR market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Cell Culture
    • 4.5.1. Cell culture market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Influenza Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. U.S. Influenza Diagnostics Market: Key Takeaways
  • 5.2. U.S. Influenza Diagnostics Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. POCT
    • 5.4.1. POCT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Laboratories
    • 5.5.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Influenza Diagnostics Market: Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. 3M
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Abbott
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. BD
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Meridian Bioscience
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Quidel Corporation
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. SA Scientific Ltd.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. SEKISUI Diagnostics
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Thermo Fisher Scientific Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 3 U.S. influenza diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. influenza diagnostics: Market outlook
  • Fig. 9 U.S. influenza diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. influenza diagnostics market driver impact
  • Fig. 14 U.S. influenza diagnostics market restraint impact
  • Fig. 15 U.S. influenza diagnostics market strategic initiatives analysis
  • Fig. 16 U.S. influenza diagnostics market: Test type movement analysis
  • Fig. 17 U.S. influenza diagnostics market: Test type outlook and key takeaways
  • Fig. 18 RIDT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 RT-PCR market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cell culture market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. influenza diagnostics market: End use movement analysis
  • Fig. 23 U.S. influenza diagnostics market: End use outlook and key takeaways
  • Fig. 24 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 POCT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)